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ABSTRACT
Human Papilloma Virus infection is very frequent in humans and is mainly transmitted sexually. The
majority of infections are transient and asymptomatic, however, if the infection persists, it can occur with a
variety of injuries to skin and mucous membranes, depending on the type of HPV involved. Some types of
HPV are classiﬁed as high oncogenic risk as associated with the onset of cancer. The tumors most
commonly associated with HPV are cervical and oropharyngeal cancer, epigenetic mechanisms related to
HPV infection include methylation changes to host and viral DNA and chromatin modiﬁcation in host
species. This review is focused about epigenethic mechanism, such as MiRNAs expression, related to cervix
and oral cancer. Speciﬁcally it discuss about molecular markers associated to a more aggressive
phenotype. In this way we will analyze genes involved in meiotic sinaptonemal complex, transcriptional
factors, of orthokeratins, sinaptogirin, they are all expressed in cancer in a way not more dependent on
cell differentiation but HPV-dependent.
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Introduction
Papillomaviruses are circular, double-stranded DNA viruses
with a size of about 8 Kb normally composed of 8 early genes
(E1-E7) and 2 late genes (L1-L2). Genes E1 and E2 express 2
regulatory proteins and 3 oncoproteins are expressed by E5, E6
and E7 genes. Genes L1 and L2 encodes for capsid proteins.
Human Papilloma Virus infection is very frequent in the
humans and is mainly transmitted sexually. The majority of
infections are transient and asymptomatic, however, if the
infection persists, it can occur with a variety of injuries to skin
and mucous membranes, depending on the type of HPV
involved. Some types of HPV are classiﬁed as high oncogenic
risk as associated with the onset of cancer. The tumor most
commonly associated with HPV is the cervical cancer which is
the ﬁrst cancer to be recognized by the World Health Organiza-
tion (WHO) entirely due to an infection. The known types of
papilloma viruses are 160,1 divided into 16 groups progressively
designated with the letters A to P on the basis of their DNA
sequence homologies. Papilloma viruses are also classiﬁed in
skin and mucous according to their tissue speciﬁcity. Most of
the viruses of this family do not cause serious diseases, such as
skin warts. Some, however, may cause benign tumors such as
genital wart and even malignant such as cancer of the cervix,
the mouth, the anus, esophagus and the larynx. In particular,
carcinomas of the uterine cervix are triggered by genotypes 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, where the types 16 and
18 are the most frequent, while the simple warts and warts are
generated by genotypes 2, 7 (common warts), 1, 2, 4 (plantar
warts) and 3, 10 (ﬂat warts).
The HPV involvement in oral carcinogenesis was ﬁrst pro-
posed in 1983 by Syrjanen et al.2 Nevertheless, the association
between HPV and oral squamous cell carcinoma (OSCC) is
until now not well deﬁned, especially because of the wide range
of HPV DNA detection in OSCC, varying from 0–100%.3-5 Bas-
ing on their association with cervical carcinogenesis, HPV types
are classiﬁed as “low risk” (LR HPV), such as HPV-6 and ¡11,
which are found in benign epithelial proliferations, and “high-
risk” HPV (HR HPV), such as HPV-16 and 18, which are
detected in up to 99% of high-grade cervical squamous intrae-
pithelial lesions and invasive cervical carcinomas (CC). The
expression of oncogenic HPV proteins (E5, E6, E7) should be
able to down-regulate critical tumor suppressor (p53, pRB,
p-16) in head and neck cancers comparing them to analog ﬁnd-
ings in cervical cancers (Fig. 1). The early virus proteins E6 and
E7 act synergistically in maintaining the neoplastic cell pheno-
type preventing apoptosis. The combined actions of these onco-
proteins, leads to p53 degradation, anti-apoptotic signaling and
CONTACT Marina Di Domenico marina.didomenico@unina2.it Department of Biochemistry, Biophysics and General Pathology, University of Campania
“Luigi Vanvitelli,” Via Luigi De Crecchio, 7 80138 Naples, Italy.
© 2018 Taylor & Francis Group, LLC
CANCER BIOLOGY & THERAPY
2018, VOL. 19, NO. 10, 850–857
https://doi.org/10.1080/15384047.2017.1310349
cell cycle promotion. Due to their binding properties and inac-
tivating tumor suppressor genes such as p53 and Rb, proteins
encoded by the viral genome promote intense cellular replica-
tion producing the formation of papillomas, warts, focal epithe-
lial hyperplasia and cancers. The mechanisms that control the
gene expression of HPV involve DNA methylation. The tran-
scription of proteins E6 and E7 is directed by regulatory ele-
ments in the Long Control Region (LCR), which also contain
the binding sites for the viral protein E2 that regulates the
oncogene, expression. Since the majority of human neoplasms
are characterized by the imbalance of the regulatory cell-cycle
control processes, the expression study of proteins involved in
the critical check-points of cell growth could elucidate the
effects of the alteration of the cell death and growth ratio on
the carcinogenetic process. Major efforts are currently made
toward the chance to interfere with the 3 major anti- prolifer-
ative pathways inﬂuencing oncogenesis, namely, inhibition of
cell growth, induction of differentiation and apoptosis. The
proteins codiﬁed by the gene family of Inhibitor of Apoptosis
(IAP) target a downstream step in apoptosis. Survivin is a
recently characterized IAP protein, which is abundantly
expressed in most solid and haematologic malignancies, but
undetectable in normal adult tissues. Recent studies have also
shown a survivin overexpression in oral SCC and a possible
relation between HPV positivity and survivin expression.3 A
possible role of survivin in cervical carcinogenesis has been
suggested.
Survivin expression tends to increase along with tumor pro-
gression and seems to be more closely related to the progres-
sion of cervical SCC compared with Fas-ligand, Fas and bcl¡2.
The ﬁrst cause of death for oral SCC are nodal metastases; their
incidence is signiﬁcantly correlated with the loss of intercellular
adherence of tumor cells. Intercellular adhesiveness is mediated
by a glycoproteins family, named cadherins. In epithelial cells,
homotypic cell-cell adhesiveness is mediated by epithelial-cad-
herin (E-cad). Down-regulation of E-cadherin was reported to
be directly related to invasiveness and progression of many
human epithelial tumors.6 The importance of catenins in tumor
progression has been suggested by the identiﬁcation of tumor
cell lines lacking b- or gamma-catenin.7 Normally, catenins are
membranous proteins and the free cytoplasmic pool of b-cate-
nin is small. In fact, activated protein C (APC) forms a complex
with b-catenin, axin and GSK-3b, which promotes the rapid
degradation of b-catenin.8 Elevation of the free pool of cyto-
plasmic b-catenin is the result of the inactivation of the APC-
system or activation of the WNT-1 pathway. Normally, the
WNT signal stabilizes free b-catenins, while mutation in APC
or b-catenin mimic WNT signaling, stimulating cell prolifera-
tion or antagonizing apoptosis.9 Some studies have investigated
the possible role of catenins in oral SCC.10,11 A study supports
the existence of an inverse relationship between the expression
of b and gamma catenin and the degree of cellular differentia-
tion,12 as well the reduced expression of b and/or gamma cate-
nin seems to be related with the progression of cervical SCC.13
The transformation of human keratinocyte infected by HPV
requires activation of the WNT pathway; this activation may
serve as a screening tool in HPV-positive populations to detect
malignant progression.14 In the last decade the scientiﬁc
research has shown a growing interest on several biologic
markers (e.g. MIB-1, PCNA, cyclin D1) expressed during the
cell cycle to use them as indexes of oral-cervical SCC progres-
sion and aggressiveness, also in relation to HPV-DNA detec-
tion. On the basis of these tendencies, the present review aims
to examine the molecules involved in the control of cellular
proliferation, like PCNA, Mib-1 and cyclin D1. In this regard
an high expression of PCNA was found in oral and cervical
SCC HPV-positive, due to HPV-related oncogenetic promo-
tion.15 Other studies, have been shown an aberrant expression
of cyclin D1 in the majority of oral and cervical SCC: this situa-
tion resulted tightly related to their unfavorable prognosis.16
Immunohistochemical detection of MIB1 (Ki-67) has been sug-
gested to determine proliferation index in oral and cervical
SCC.17 Toll-like receptors (TLRs) are present on numerous cell
types, also in human cells and have the ability to detect and
bind distinct pathogen-associated ligands, thus signaling the
presence of an invading microbe and consequently initiating an
immune response against it.18 In this review we will discuss
about the expression of different type of TLRs in HPVC and
HPV- lesions to deﬁne the expression of receptor proteins asso-
ciated with host immune response against virus infected cervix
and oral cancerous cells.
Recent studies indicate that epigenetic regulation of gene
expression has emerged as a fundamental pathway in the path-
ogenesis of numerous malignancies, including cancers of the
oropharyngeal tract.19,20 Particular interest has been dedicated
to the epigenetic silencing of SFRPs, WIF1 and DKK3 with the
following chronic activation of WNT. Inactivation of several
tumor-suppressor genes has been also attributed to aberrant
hyper-methylation of their promoter regions (E-cadherin, p16,
p15, hMLH1, hMSH2, MGMT, DAPK, RUNX3). We focus on
small noncoding RNAs (MiRNAs) which play an essential role
in the epigenetic regulation of gene expression. MiRNAs’ func-
tion in the regulation of gene expression by binding the tran-
scription product (mRNAs), and causing its degradation or
blocking its translation.21,22
MicroRNAs are considered useful early diagnostic and prog-
nostic markers of cancer, candidates for therapeutic interven-
tion, and targets for basic biomedical research, also in cervix
Figure 1. HPV Infections and malignant transformation of the epithelial cells.
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and oropharyngeal cancers. We will focus on the epigenetic
regulation of multiple genes may be considered a common
event in cancer.
The basis of HPV pathogenesis
It is by now assessed that the persistent infection of high-risk
HPV is the main cause of cervical cancer. As reported in litera-
ture cervical cancer is the second most common cancer among
women. Among 160 HPV genotypes 13 are classiﬁed as high-
risk types regard the development of cervical cancer with the
most common types 16 and 18. Since HPV transmission occurs
mainly by skin-to-skin contact it is greatly inﬂuenced by sexual
activity, especially among individuals having multiple partners.
Furthermore, the virus is particularly resistant to heat and
dehydration thus its propagation can occur by exposure to con-
taminated clothes.
The HPV infection proceeds through the binding of L1 cap-
sid protein with the cellular membrane receptors of cervical
epithelial cells, heparin sulfate proteoglycan molecules exposed
on the cell surface are engaged in the binding. As consequence
of binding to proteoglycan the capside undergoes to a confor-
mational change triggers by cyclophilin B which enhance the
infection, thus promoting initiation and progression of cancer.
Indeed, multiple receptors interactions were found to be
involved in the binding,23 it has been hypothesized that the
HPV infection involves several proteins among which HSPGs
(HvSPG2 and SDC2), CyPB(PPIB), a 6 integrin (ITGA6), tet-
raspanins(TSPAN1), GFR(EGFR and FGFR2) and A2t. Fur-
thermore, it has been found that receptor genes possess single
nucleotide polymorphisms (SNP) expressing a certain variabil-
ity which can affect the virus infection process and outcome of
diseases. Thus the cervical lesions progression could be
depended by the receptor gene other than virus variability. This
ﬁnding increases the uncertainty in the prognosis of infection.
Recently,24 a paper concerning a case-control study of 1584
cases shows that TNFAIP8 a protein induced by tumor necrosis
factor-a is associated with oral and cervical cancer risk.
TNFAIP8 family expresses anti-apoptotic and pro-oncogenic
activity, a single nucleotide polymorphisms of TNFAIP8 gene
(TNFAIP8-rs11064 SNP) has found to be responsible of an
increase of cancer risk. In fact, TNFAIP8 expression can be reg-
ulated by this SNP gene that functions by affecting the afﬁnity
of miR-22 binding to the 3-UTR of TNFAIP8.
HPV gene proﬁle in oral and uterus cervix cancers
Epigenetic and Genetic proﬁle may be useful in clinical prac-
tice, improving the current diagnostic tools and contributing
indirectly, together with the classical histo-pathological param-
eters, to therapeutics as predictor of choice for the correct clini-
cal management of patients. The epigenetic ﬁngerprint of HPV
related HN-cancer is very different from HPV unrelated can-
cers. Epigenetic ﬁngerprint together with gene expression panel
can differentiate cancers with opposite therapeutical strategies.
In fact HPV related cancers are chemo- and radiotherapy sensi-
tive whereas HPV unrelated cancer need the development of
new therapy.
Despite being more advanced at diagnosis, HPV-positive
head and neck SCC (HNSCC) is associated with better response
to current radio-chemotherapy and longer survival than HPV-
negative tumors. Thus, HPV-positive and- negative HNSCC
appear to be clinically and biologically distinct.
Several studies, primarily on the high risk HPV16, have
documented that the viral genome methylation status changes
not only during the viral life cycle but also in the context of
the progressive neoplastic disease that culminates in cancer.
Most of these studies have focused on the high risk HPV
most commonly associated with human cancer, HPV16, with
a few studies looking at other high risk HPVs. Until recently,
studies have focused on evaluating the HPV methylation sta-
tus of the long control region (LCR; also referred to as the
upstream regulatory region or URR) which contains the viral
promoter driving expression of early genes including the viral
oncogenes E6 and E7. These oncogenes are frequently found
expressed in HPV-associated neoplastic disease including can-
cers, the viral transcriptional enhancer and the viral origin of
DNA replication. Also commonly analyzed are regions neigh-
boring the LCR on the circular double stranded DNA genome,
including the 30 region of L1, which is upstream of the LCR,
and the E6 gene, which is downstream of the LCR. Studies
have used the use of methylation-sensitive restriction endonu-
cleases and/or bisulﬁte treatment to distinguish methylated
from unmethylated cytosines. In the latter case, the standard
approach consists to PCR ampliﬁcation of bisulﬁte-treated
DNA using regional speciﬁc primers followed by sequencing
of the amplimer products directly or after cloning. The latter
having the advantage that the methylation status of individual
copies of the viral genome can be identiﬁed instead of the
average methylation state of multiple genomes. More recently
deep sequencing technologies have been used to interrogate
the methylation status of bisulﬁte treated DNA, allowing one
to look at the whole viral genome, as opposed to speciﬁc
PCR-ampliﬁed regions. The general conclusions are that the
DNA methylation state of the HPV genome is dynamic both
in the context of the viral life cycle and associated neoplastic
disease. The latter point has led to the suggestion that the
methylation status of the HPV genome may be diagnostic if
not prognostic of neoplastic progression as detailed below.
The methylation dynamic status associated to neoplastic pro-
gression supports the hypothesis that epigenetic regulation of
viral gene expression is an important factor in HPV-associated
disease. Another observation is that the viral genome is likely
subjected to de novo methylation by host DNA methyltrans-
ferases (DNMTs) implicated in innate responses to pathogens.
Thus methylation of the viral genome may be in part a mech-
anism by which the host attempts to suppress viral gene
expression and thereby HPV pathogenicity (dadoi:10.1016/j.
virol.2013.07.016.).
Kim et al.25 provided the ﬁrst analysis of the methylation
status of the HPV16 genome in the context of the viral life
cycle. This study analyzed the methylation status of the LCR in
a clonal cell line, W12E, derived from an HPV16-positive
CIN,26,27 that harbors the viral genome as an extrachromo-
somal nuclear plasmid and that upon induction of differentia-
tion supports the productive stage of the viral life cycle as
evidenced by the production of virus particles.28 Their analyses
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demonstrated that host DNA methyltransferases activity modi-
ﬁed de novo the viral genome given the pattern of cytosine
methylation at not only CpG dinucleotides but other CpX
dinucleotides. They also observed, that upon induction of dif-
ferentiation, the viral LCR becomes hypomethylated, demon-
strating that the methylation status of the viral genome is
dynamic. But they also observed an increase in methylation
within the region of the LCR containing the early promoter.
Interestingly among the sites hypermethylated in the promoter
region were sites within the viral E2 transcription factor bind-
ing sites that are thought to mediate transcriptional repression
of the early promoter.
Kalantari et al.,29 who analyzed the LCR and adjoining
regions of the HPV16 genome by sequencing of bisulﬁte treated
DNA ﬁrst observed that methylation within the 3- region of the
L1 gene was associated with neoplastic progression: this region
was heavily methylated in cervical cancers but poorly methyl-
ated in low grade CINs. These ﬁndings were validated by sev-
eral follow-up studies30-33 including 2 studies that evaluated the
methylation status of the whole genome34 in which hyperme-
thylation of not only the HPV16 L1 gene but also the L2 and
E5 genes were observed in more severe oral and cervix neoplas-
tic disease (Fig. 2).
The increased methylation found in E2, L2, and L1 genes
was associated with increased risk of CIN3 in a serial sets of
samples from women. Thus increases in methylation of the
structural genes and E2 may not only be diagnostic of high
grade CIN and cancer but also of potential prognostic value in
predicting progression.
During neoplastic progression, the high risk HPV genomes
often are found to become integrated into the host genome.
Integration frequently arist fragile sites within the host genome,
sites prone to undergoing genetic recombination.35,36 These
recombination events commonly occur within the 30 early
region of the virus and often result in the deletion of 30 part of
the viral genome to the recombination break point, with con-
tinued if not enhanced expression of the 2 viral oncogenes E6
and E7.
Two types of integration are found in HPV-associated neo-
plasias.26 Type 1 integration events occur when a single copy of
the viral genome becomes integrated in the host chromosome.
Type 2 integration takes place when a concatomer of viral
genomes integrates into a site within the host chromosome. In
both cases one can ﬁnd situations in which the integrated viral
genomes and neighboring host DNA are ampliﬁed. In the cases
of type 2 integration events, it is often found that only the 30
most copy of the viral genome (the one that is disrupted by the
integration event) is transcriptionally active.
Unfortunately, sufﬁcient attention has not been given to the
state of the HPV genome in most methylation studies, and only
one study has distinguished between type 1 vs type 2 integra-
tion events. In that study using clonal W12 lines derived from
the HPV16-positive CIN,31 differences in methylation status
were observed, with type 2 integration events associated with
greater hypermethylation of the LCR. This ﬁnding is consistent
with the hypothesis that internal copies of the viral genome are
epigenetically silenced.
Oropharyngeal cancer and MiRNAs
It is believed that cancer is a genetic and epigenetic disease,
usually involving altered expression proﬁles of tumor-suppres-
sor genes and of proto-oncogenes.37 MicroRNAs (miRNAs) are
endogenous small noncoding RNAs involved in tumorigenesis.
MiRNAs have profound effects on epigenetic machinery.
Besides, their control is also affected by epigenetic mechanisms.
Indeed, a reduction in miRNAs accelerates oncogenic transfor-
mation thorough the deregulation of target oncogenes.38
MiRNAs alterations correlate with cell proliferation, devel-
opment, differentiation and metastasis in different tumor types.
Several studies focused on miRNA proﬁling in HNC have been
published in recent years.39 They have identiﬁed speciﬁc miR-
NAs as candidate oncogenes and tumor-suppressor genes in
head and neck squamous cell carcinoma.40,41 Interestingly, the
investigation of a panel of 9 head and neck cancer cell lines and
261 mature miRNA gene identiﬁed speciﬁc subsets of miRNAs
that provided candidate molecular signatures characteristic of
the tumor-derived cell lines belonging to this cancer.42 Results
showed evidence of overexpression of 33 miRNAs, beside 22
miRNAs with low levels of expression. MiR-21 showed an over-
expressed level, as for other kinds of malignancies, and was sug-
gested to be a cancer-speciﬁc miRNA.42 However, in contrast to
many cancer cell lines (breast, lung, prostate, colorectal..), head
and neck demonstrate overexpression of miR-205r that could
be a speciﬁc marker of OSCC.43 Functional changes of miRNAs
could result from their genetic variants leading to different
expressions of their target genes. Furthermore, a polymorphism
in the complementary miRNA-binding site could also lead to
miRNA disrupted expression. An SNP at the miR-885–5p or
the let-7 binding sites have been associated with an increased
risk of HNSCC and reduced survival.44,45
Although distinct miRNA proﬁles were shown in head and
neck cancer only a few studies analyzing the miRNA proﬁle in
HNC with regard to HPV presence have been published to
date. More than smoking and alcohol consumption, HPV
infection is also recognized as another primary cause of
HNC.46 A recent study proﬁled HPV-positive and HPV-nega-
tive of HNC and identiﬁed the “HPV core” miRNAs. High-risk
HPV infection leads to aberrant expression of cellular onco-
genic and tumor suppressive miRNAs.47
Many researchers have focused on the occurrence of epige-
netic phenomena in OSCC development48 Epigenetic changes
represent an important mechanism for the silencing of tumor
suppressor genes.49 Further miRNA genes are subject to
Figure 2. The Interplay of HPV-regulated miRNAs with malignant transformation in
oral and cervical cancer.
CANCER BIOLOGY & THERAPY 853
epigenetic changes. In fact, deregulation of DNA methylation
alter the expression of some miRNAs. Hypermethylation causes
downregulation of potentially tumor suppressive miRNAs such
as miR-137 and ¡193a.22,50,51 Whereas hypomethylation can
cause overexpression of miRNA genes such as miR-663, which
has been found to induce chemotherapy resistance in cancer.52
Similarly the promoter regions associated with speciﬁc
miRNAs can also be abnormally methylated leading to up or
downregulation, as in the case of miR-137. This has shown
some promise as a biomarker for Head Neck Squamous
Carcinoma.53
It is urgently needed to develop biomarkers for early clinical
detection, diagnosis, prognosis, and novel effective therapies
for oral carcinoma.43 The knowledge of miRNA and its poten-
tial to play critical roles in a broad range of biologic activities,
therefore creates new understanding of head and neck cancer
development. Altered expression of miRNAs could be novel
molecular biomarkers for the deﬁnite diagnosis of cancer, met-
astatic site, cancer stage, and its progression
Several attempts have been made by researches to identify a
speciﬁc biomarker for a timely diagnosis and progression mon-
itoring, at moment the more promising markers seem to be the
speciﬁc virus DNA methylation or miRNA. However, ﬁnal goal
in the study of HPV infection will be to understand how the
virus escapes the host immune system, the knowledge of this
mechanism could open the door to a deﬁnitive therapy for this
desease.
Cervical cancer and MiRNAs
Cervical cancer is one of the most common cancers in women
worldwide that results of multistep process. Cervical cancer is
usually associated with high-risk human papillomaviruses,
which stratiﬁcation of histological types from normal through
to invasive carcinoma is well characterized and supported by
molecular techniques based on HPV genotyping.54 However,
such infection is not sufﬁcient to induce the malignant trans-
formation. Hence, there is an urgent need for the identiﬁcation
of rapid and efﬁcient molecular biomarkers of screening and
diagnosis.
MicroRNAs are small non-coding RNAs with important
functions in several biologic, and deregulation of these mole-
cules was widely associated with human pathologies. Micro-
RNA expression is severely disrupted in carcinogenesis and
speciﬁc dysregulated miRNAs may act as biomarkers of
patients’ outcome in different neoplasias.55 Further, recent
studies have shown that miRNA levels are signiﬁcantly deregu-
lated in a range of cancers including cervical cancer.56 Indeed, a
lot of miRNAs have been described to be closely associated
with prognosis and susceptibility of cervical cancer. Further-
more, miRNAs acting as oncogenes (oncomiRs) or tumor sup-
pressors, play important role in the regulation of numerous
biologic processes such as cell proliferation, apoptosis, invasion
and migration in cervical cancer.57,58
Several reports showed speciﬁc overexpression or underex-
pression of miRNAs in cervical cancer tissues or cell lines com-
pared with normal cervical epithelial tissues that differ
according to the particular tumor types.59 Signature of miRNA
expression in different histological samples, from normal to
invasive cancer, is sometimes heterogeneous. Globally, many
microarrays and TaqMan quantitative real-time polymerase
chain reaction (PCR) analysis have demonstrated a highly pref-
erential increased expression of recognized oncomirs such
miR-20a,60 miR-21,61 miR-24,mir-146a, miR-155, miR-205 in
cervical cancer. However, many others miRNAs are downregu-
lated (e.g., miR-34a, miR-100, miR-let7b, miR-143, miR-
145).62,63
Interestingly, the altered regulation of cellular oncogenic
and tumor-suppressive miRNAs has been reported in asso-
ciation with HPV infection and cervical cancer. In high-risk
HPV infections, several studies have been addressing on the
impact of viral oncoproteins interactions with the aberrant
expression of multiple miRNAs.64,65 Indeed, changes in the
expressions of multiple miRNAs such as miR-34a,miR-218,
miR-29a and miR-146a are attributed to interactions with
viral oncoproteins E5, E6 and E7, which subsequently con-
tribute to the initiation and progression of cervical cancer.66
Yet, the detailed network of the events has not been fully
elucidated. Expression level of miR-29 is upregulated in cer-
vical cancer, and was suggested to be regulated by HPV
oncoproteins E6/E7.67 In contrast, miR196a expression is
reduced in HPV16- positive cervical cancer cell lines. It has
been suggested that HPV16 E5 speciﬁcally down-regulates
miR196a upon infection of the human cervix facilitating the
transformation of normal cervix cells to cervical carci-
noma.68,69 Further, miR-34a showed also a reduced expres-
sion occurring in an early-onset event in the development
of HPV associated cervical cancer. The oncoprotein E6 was
suggested to reduce miR-34a expression in the p53-depen-
dent pathway during precancerous lesions, although the
exact mechanisms remain unclear.70 miR-100 expression
showed a reduced level in late phase of HPV associated cer-
vical carcinogenesis. But, miR-100 inhibition would not be
directly affected by HPV E6/E7 in cervical cells. Further-
more, HPV oncoproteins have reported to regulate crosstalk
between miRNA levels and key cellular signaling pathways
such STAT3.71 It is well known that STAT3 play a crucial
role that links chronic inﬂammation to cancer. Lee et al.
strongly indicated a functional implication of altering levels
of either miR-21, let-7a or STAT3 signaling on each other
in cervical cancer cell lines and the loop was found con-
trolled by HPV oncoprotein E6.72 Besides, miRNAs, such as
miR-125b and miR-203 seem to play an important role in
the regulation of viral gene expression and DNA replication.
Conclusions
Collectively, several results support the involvement of miRNA
in the pathogenesis and development of oral and cervical can-
cer. Further investigations are needed to bring more discoveries
on miRNAs to develop new biomarkers associated to tumor
progression, clinical outcome, or use them as therapeutic agents
for these cancers.
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